Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8453579 | Lung Cancer | 2018 | 15 Pages |
Abstract
Crizotinib treatment for patients with EGFR mutation positive NSCLC that acquire cMET amplification after EGFR TKI treatment results in short-lived and often heterogeneous responses, possibly due to subclonality of cMET-driven resistance and co-occurrence of other EGFR TKI resistance mechanisms.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Bianca van Veggel, Adrianus J. de Langen, Sayed Hashemi, Kim Monkhorst, Efraim H. Rosenberg, Daniëlle A.M. Heideman, Teodora Radonic, Egbert F. Smit,